Search research articles
Contact Us
Filters
Showing results (61-70 of 223) with videos related to
Page
of 23
Sort By:
The Prostate
|
May 24, 2007
Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models
David Z Qian, Yong-Feng Wei, Xiaofei Wang, et al.
Cancers
|
June 26, 2025
Counties with Low Employment and Education Status Are Associated with Higher Age-Adjusted Cancer Mortality
Minu Ponnamma Mohan, Joel B Epstein, Kapil S Meleveedu, et al.
Geriatrics (Basel, Switzerland)
|
January 17, 2023
Telemedicine: Issues in the Analysis of Its Use in Elderly People and in People with Disabilities, According to the Perspective of the Clinical Psychology of Disability
Donatella Rita Petretto, Luca Gaviano, Gian Pietro Carrogu, et al.
Research Square
|
October 7, 2024
Measurement of Patients' Acceptable Symptom Levels and Priorities for Symptom Improvement in Advanced Prostate Cancer
Stella Snyder, Ekin Secinti, Ellen Krueger, et al.
Oncotarget
|
October 29, 2013
Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer
Leigh Ellis, Sheng Yu Ku, Swathi Ramakrishnan, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
December 12, 2024
Cancer treatment-induced ulcerative mucositis serves as a significant predictor of burden of illness including dysphagia, and associated disparities among hospitalized cancer patients
Minu Ponnamma Mohan, Roberto Pili, Joel B Epstein, et al.
Molecular Cancer Therapeutics
|
November 16, 2011
Vascular disruption in combination with mTOR inhibition in renal cell carcinoma
Leigh Ellis, Preeti Shah, Hans Hammers, et al.
BMC Cancer
|
July 19, 2012
Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition
Sreenivasulu Chintala, Tanbir Najrana, Karoly Toth, et al.
Pharmaceuticals (Basel, Switzerland)
|
April 26, 2025
Hospitalized Cancer Patients with Opioid Management for Chemo-Induced Ulcerative Mucositis Lessens the Patients' Overall Burden of Illness
Minu Ponnamma Mohan, Joel B Epstein, Kapil S Meleveedu, et al.
Clinical Practice and Epidemiology in Mental Health : CP & EMH
|
April 25, 2024
Telemedicine, e-Health, and Digital Health Equity: A Scoping Review
Donatella Rita Petretto, Gian Pietro Carrogu, Luca Gaviano, et al.
Page
of 23
Search research articles
Search
Showing results (61-70 of 223) with videos related to
Sort By:
Page
of 23
The Prostate
|
May 24, 2007
Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models
David Z Qian, Yong-Feng Wei, Xiaofei Wang, et al.
Cancers
|
June 26, 2025
Counties with Low Employment and Education Status Are Associated with Higher Age-Adjusted Cancer Mortality
Minu Ponnamma Mohan, Joel B Epstein, Kapil S Meleveedu, et al.
Geriatrics (Basel, Switzerland)
|
January 17, 2023
Telemedicine: Issues in the Analysis of Its Use in Elderly People and in People with Disabilities, According to the Perspective of the Clinical Psychology of Disability
Donatella Rita Petretto, Luca Gaviano, Gian Pietro Carrogu, et al.
Research Square
|
October 7, 2024
Measurement of Patients' Acceptable Symptom Levels and Priorities for Symptom Improvement in Advanced Prostate Cancer
Stella Snyder, Ekin Secinti, Ellen Krueger, et al.
Oncotarget
|
October 29, 2013
Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer
Leigh Ellis, Sheng Yu Ku, Swathi Ramakrishnan, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
December 12, 2024
Cancer treatment-induced ulcerative mucositis serves as a significant predictor of burden of illness including dysphagia, and associated disparities among hospitalized cancer patients
Minu Ponnamma Mohan, Roberto Pili, Joel B Epstein, et al.
Molecular Cancer Therapeutics
|
November 16, 2011
Vascular disruption in combination with mTOR inhibition in renal cell carcinoma
Leigh Ellis, Preeti Shah, Hans Hammers, et al.
BMC Cancer
|
July 19, 2012
Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition
Sreenivasulu Chintala, Tanbir Najrana, Karoly Toth, et al.
Pharmaceuticals (Basel, Switzerland)
|
April 26, 2025
Hospitalized Cancer Patients with Opioid Management for Chemo-Induced Ulcerative Mucositis Lessens the Patients' Overall Burden of Illness
Minu Ponnamma Mohan, Joel B Epstein, Kapil S Meleveedu, et al.
Clinical Practice and Epidemiology in Mental Health : CP & EMH
|
April 25, 2024
Telemedicine, e-Health, and Digital Health Equity: A Scoping Review
Donatella Rita Petretto, Gian Pietro Carrogu, Luca Gaviano, et al.
Page
of 23